15-Deoxy-∆-12,14-Prostaglandin J2 (15d-PGJ2), an Endogenous Ligand of PPAR-γ: Function and Mechanism

IF 3.5 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

PPAR Research Pub Date : 2019-08-01 DOI:10.1155/2019/7242030

Jingjing Li, Chuanyong Guo, Jianye Wu

引用次数: 59

Abstract

15-Deoxy-∆-12,14-prostaglandin J2 (15d-PGJ2), a natural peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, has been explored in some detail over the last 20 years. By triggering the PPAR-γ signalling pathway, it plays many roles and exerts antitumour, anti-inflammatory, antioxidation, antifibrosis, and antiangiogenesis effects. Although many synthetic PPAR-γ receptor agonists have been developed, as an endogenous product of PPAR-γ receptors, 15d-PGJ2 has beneficial characteristics including rapid expression and the ability to contribute to a natural defence mechanism. In this review, we discuss the latest advances in our knowledge of the biological role of 15d-PGJ2 mediated through PPAR-γ. It is important to understand its structure, synthesis, and functional mechanisms to develop preventive agents and limit the progression of associated diseases.

查看原文本刊更多论文

15-脱氧-∆-12,14-前列腺素J2（15d-PGJ2），PPAR-γ的内源性配体：功能和机制

15-Deoxy-∆-12,14-前列腺素J2 (15d-PGJ2)是一种天然过氧化物酶体增殖物激活受体-γ (PPAR-γ)激动剂，在过去的20年里，人们对其进行了详细的研究。它通过触发PPAR-γ信号通路发挥多种作用，具有抗肿瘤、抗炎、抗氧化、抗纤维化和抗血管生成等作用。虽然已经开发了许多合成的PPAR-γ受体激动剂，但作为PPAR-γ受体的内源性产物，15d-PGJ2具有快速表达和促进自然防御机制的有益特性。在这篇综述中，我们讨论了通过PPAR-γ介导的15d-PGJ2生物学作用的最新进展。了解其结构、合成和功能机制对开发预防药物和限制相关疾病的进展具有重要意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

PPAR Research MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

6.20

自引率

3.40%

发文量

审稿时长

12 months

期刊介绍： PPAR Research is a peer-reviewed, Open Access journal that publishes original research and review articles on advances in basic research focusing on mechanisms involved in the activation of peroxisome proliferator-activated receptors (PPARs), as well as their role in the regulation of cellular differentiation, development, energy homeostasis and metabolic function. The journal also welcomes preclinical and clinical trials of drugs that can modulate PPAR activity, with a view to treating chronic diseases and disorders such as dyslipidemia, diabetes, adipocyte differentiation, inflammation, cancer, lung diseases, neurodegenerative disorders, and obesity.